Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Research shows chemotherapy has no negative effects on babies in utero

Prof Frederic Amant - University Hospital Leuven, Leuven, Belgium
Research shows chemotherapy has no negative effects on babies in utero ( Prof Frederic Amant - University Hospital Leuven, Leuven, Belgium )
1 Oct 2014

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Dr Caroline Robert - Gustave Roussy, Villejuif, France
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )
29 Sep 2014

Nivolumab potentially superior to standard chemo in advanced melanoma

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab potentially superior to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
29 Sep 2014

Targeted therapy for iodine-refractory thyroid cancer

Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan
Targeted therapy for iodine-refractory thyroid cancer ( Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan )
29 Sep 2014

Questions raised about the future of lung cancer vaccination?

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium
Questions raised about the future of lung cancer vaccination? ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )
29 Sep 2014

PD-L1 protein a possible immunotherapy target in mesothelioma

Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland
PD-L1 protein a possible immunotherapy target in mesothelioma ( Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland )
29 Sep 2014

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Dr Caroline Robert - Gustave Roussy, Villejuif, France
Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )
29 Sep 2014

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2014

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
29 Sep 2014

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium
Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )
28 Sep 2014

Molecular targeting in cancer and the impact on personalised medicine

Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria
Molecular targeting in cancer and the impact on personalised medicine ( Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria )
28 Sep 2014

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014